Estimated Molecular Structure of a Carbon Nanotubec Molecular Heater Based on Binding Properties to a Target Protein
Source abstract
Abstract
Background Carbon nanotubes exhibit strong absorbance in the near-infrared (NIR) region and are considered as potent candidates for hyperthermic therapy because they generate significant amounts of heat upon excitation with NIR light. We prepared a single-walled carbon nanotube (SWNT)/IgG complex to use as a “smart molecular heater” for hyperthermic therapy. Purpose The aim of the present study was to assess the binding efficiency of DNA-functionalized SWNT/IgG complexes to a target protein. Methods 3 types of complexes with different lengths of spacer arm chain (13.5, 29, and 56 Å) linked to biotinylated IgG were prepared, and we evaluated the effect of the spacer arm length on the specificity, affinity, and capacity of binding to a target protein. Results Complexes with longer spacer lengths showed increased binding affinity to a target protein. This could be due to a reduction in steric hindrance by increasing the segmental flexibility of the spacer arm. Conclusions The results of this study suggested that DNA-functionalized SWNT/IgG complexes could act as a heating nano-device for hyperthermic cancer therapy, and the complexes can bind various types of tumor by modifiying the specific antibody.
Source: crossref · Quality: baseline
Research context
OpenAlex topics: Carbon Nanotubes in Composites · Nanoplatforms for cancer theranostics · Nanoparticle-Based Drug Delivery
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Department of Dental Engineering, Biomaterials Section, Fukuoka Dental College, Fukuoka - Japan
Department of Physiological Science and Molecular Biology, Section of Cellular and Molecular Regulation, Fukuoka Dental College, Fukuoka - Japan
References (28)
Show source-provided references
1. 10.1016/j.mser.2003.10.00110.1016/j.mser.2003.10.001 ↗
2. 10.1002/smll.20040011810.1002/smll.200400118 ↗
3. 10.1016/j.carbon.2006.02.03810.1016/j.carbon.2006.02.038 ↗
4. 10.1166/jnn.2007.30710.1166/jnn.2007.307 ↗
5. 10.1126/science.122245310.1126/science.1222453 ↗
6. 10.1007/s12274-009-9009-810.1007/s12274-009-9009-8 ↗
7. 10.1088/0957-4484/14/10/30510.1088/0957-4484/14/10/305 ↗
8. 10.1039/b410943k10.1039/b410943k ↗
9. 10.1088/0957-4484/18/41/41200110.1088/0957-4484/18/41/412001 ↗
10. 10.1021/nl062306v10.1021/nl062306v ↗
11. 10.1016/j.drudis.2010.04.00510.1016/j.drudis.2010.04.005 ↗
12. 10.1039/C0JM02020F10.1039/C0JM02020F ↗
13. 10.1158/0008-5472.CAN-10-025010.1158/0008-5472.CAN-10-0250 ↗
14. Burlaka A · Exp Oncol · 2010 · 32 · 48
15. 10.1109/TBME.2010.204259710.1109/TBME.2010.2042597 ↗
16. 10.2174/187593350110301002410.2174/1875933501103010024 ↗
17. Jyoti V · Int J Nanomedicine · 2014 · 9 · 268310.2217/nnm.14.172 ↗
18. Burke AW · J Mol Biomarkers Diagn · 2012 · S8
19. 10.2147/IJN.S3420210.2147/IJN.S34202 ↗
20. 10.2147/IJN.S1717510.2147/IJN.S17175 ↗
21. 10.1021/bm020116i10.1021/bm020116i ↗
22. 10.1021/ac702290z10.1021/ac702290z ↗
23. 10.1016/S0039-9140(01)00490-810.1016/S0039-9140(01)00490-8 ↗
24. 10.1016/S0040-6090(96)08830-X10.1016/S0040-6090(96)08830-X ↗
25. 10.1038/nmat87710.1038/nmat877 ↗
26. 10.1016/j.cplett.2008.02.08910.1016/j.cplett.2008.02.089 ↗
27. 10.1073/pnas.050268010210.1073/pnas.0502680102 ↗
28. 10.1117/1.307880310.1117/1.3078803 ↗